Our Equity Story
Development of Radiopharmaceuticals with a Theranostic Approach for Improved Treatment Outcomes
Pentixapharm develops radioligand programs for the diagnosis and treatment of cancer and other widespread diseases. This unique combination is called theranostics (therapy + diagnostics).
The theranostic approach allows for detecting diseased cells, fighting them, and closely monitoring the disease progression and treatment response (fight, find, follow). The choice of radioisotope determines the outcome: weaker isotopes are used for imaging, while high-energy isotopes are intended to destroy the targeted disease-relevant cells.
Many of Pentixapharm’s development programs are first-in-disease for radiopharmaceuticals, such as various types of blood cancer or primary aldosteronism, a major cause of high blood pressure that is currently under-diagnosed and thus inadequately treated.
Innovative Product Candidates with Near-Term Market Approval Potential
Building a broad pipeline for the treatment of various types of blood cancers such as multiple myeloma, CNS lymphoma, T-cell lymphoma, or acute myeloid/lymphoid leukemia, as well as cardiovascular, endocrine, and inflammatory diseases.
Diagnostic lead candidate PentixaFor is already in Phase III clinical development for primary aldosteronism in Europe; preparations for a pivotal Phase III clinical trial in the U.S. are underway, expected to begin in 2025.
For therapeutics lead candidate PentixaTher, which targets difficult-to-treat B- and T-Cell Lymphomas, a Phase I/II clinical trial is underway to confirm promising initial results. First Results are expected in early 2026
Clear Focus on a Well-Researched Target
Exclusive worldwide rights to a patent family developed by the University of Munich around radioisotope-labeled molecules targeting the cell membrane receptor CXCR4. This protein plays a key role in tumor growth, metastasis, and the development of inflammatory processes.
A unique network provides a large data pool and commercial rights to over 20 investigator-initiated studies to accelerate pipeline development.
International Growth Market with High M&A Activity
Increasing medical relevance and high economic potential of radiopharmaceutical therapies.
Radiotherapeutic approaches are of great significance for healthcare systems, as they offer high benefits for patients through better sensitivity and efficacy and have the potential to reduce long-term treatment costs.
In the last 12 months alone, several international M&A transactions in the radiopharmaceutical market have totaled over USD 8 billion.
Experienced Team and Strong Lead Investor
Many years of expertise in the radiopharmaceutical sector as a subsidiary of the Eckert & Ziegler Group, one of the world’s largest providers of isotope technology for medical, scientific, and industrial applications.
A first-class leadership team with extensive experience in >100 clinical studies and >10 approvals is driving the growth strategy forward.
Dr. Andreas Eckert, founder of Eckert & Ziegler, with 25 years of successful radionuclide commercialization, is a committed lead investor and chairman of the supervisory board.
Spin-Off from Eckert & Ziegler SE Offers Exciting Opportunity in Radiopharmaceuticals
Pentixapharm plans an IPO on the Frankfurt Stock Exchange in Q4 to strategically position itself in an international growth market with high M&A activity and to expand short-term financial resources for further pipeline development and secure long-term capital access.
The spin-off enables targeted investor outreach and greater flexibility as an independent company to successfully advance research and development projects.